Christopher Quinn
About Christopher Quinn
Christopher Quinn is a Principal Scientist with extensive experience in biochemistry and drug research. He has worked at several prominent institutions, including the Genomics Institute of the Novartis Research Foundation and Novartis Institutes for BioMedical Research, and currently holds a position at MOMA Therapeutics.
Work at MOMA Therapeutics
Christopher Quinn has been serving as a Principal Scientist at MOMA Therapeutics since 2021. His role involves leading research initiatives aimed at advancing therapeutic solutions. MOMA Therapeutics focuses on developing innovative treatments, and Quinn's expertise contributes to the organization's mission in the biotechnology sector. He operates from the company’s location in Boston, Massachusetts.
Education and Expertise
Christopher Quinn earned a Bachelor of Science degree in Biochemistry from Northeastern University, where he studied from 1996 to 2001. His educational background provides a strong foundation for his career in scientific research and development. Quinn's expertise lies in biochemistry, which he has applied throughout his professional journey in various research roles.
Background in Research
Prior to his current position, Christopher Quinn held several significant roles in the research field. He worked as a Laboratory Associate at Charles River Laboratories from 2001 to 2002. Following that, he served as a Senior Research Associate at Abbott Bioresearch Center from 2002 to 2008. Quinn then transitioned to the Novartis Institutes for BioMedical Research (NIBR) as a Principal Scientist, where he worked from 2010 to 2021. He also spent two years as a Scientist at the Genomics Institute of the Novartis Research Foundation from 2008 to 2010.
Career Progression
Christopher Quinn's career reflects a steady progression through various roles in the biotechnology and pharmaceutical industries. After starting as a Laboratory Associate, he advanced to Senior Research Associate at Abbott Bioresearch Center. His tenure at Novartis Institutes for BioMedical Research as a Principal Scientist spanned eleven years, showcasing his ability to contribute to significant research projects. This trajectory led him to his current role at MOMA Therapeutics, where he continues to apply his extensive experience.